⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent melanoma of the skin

Every month we try and update this database with for recurrent melanoma of the skin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635
Colorectal Aden...
Metastatic Panc...
Recurrent Breas...
Recurrent Color...
Recurrent Melan...
Recurrent Non-S...
Recurrent Pancr...
Recurrent Renal...
Solid Neoplasm
Stage IV Breast...
Stage IV Non-Sm...
Stage IV Renal ...
Stage IV Skin M...
Stage IVA Color...
Stage IVA Pancr...
Stage IVB Color...
Stage IVB Pancr...
Cyclophosphamid...
Laboratory Biom...
Pegfilgrastim
Pharmacological...
TLR8 Agonist VT...
18 Years - Mayo Clinic
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid TumorsNCT02650635
Colorectal Aden...
Metastatic Panc...
Recurrent Breas...
Recurrent Color...
Recurrent Melan...
Recurrent Non-S...
Recurrent Pancr...
Recurrent Renal...
Solid Neoplasm
Stage IV Breast...
Stage IV Non-Sm...
Stage IV Renal ...
Stage IV Skin M...
Stage IVA Color...
Stage IVA Pancr...
Stage IVB Color...
Stage IVB Pancr...
Cyclophosphamid...
Laboratory Biom...
Pegfilgrastim
Pharmacological...
TLR8 Agonist VT...
18 Years - Mayo Clinic
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: